News|Articles|November 18, 2024
Elevating and De-Risking Your Drug Portfolio Strategy With AI
Author(s)Intelligencia AI
Artificial intelligence (AI) can improve risk assessment and decision-making in drug development by applying objective, data-driven criteria consistently. Companies should focus on the quality of data, selecting the right AI use cases, and leveraging external partners to maximize the potential of AI.
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Trending on PharmExec
1
Novo Nordisk Stock Reacts to Recent Board Changes
2
MJH Life Sciences Acquires BPD Healthcare, Expands Reach Among Health Systems and Innovators
3
Bob Mauch: Strengthening the Chain
4
Takeda and Innovent Biologics Announce Strategic Global Partnership
5
